Gilead’s Trodelvy Outperforms Expectations In Breast Cancer, Again
The company is presenting overall survival data in HR+/HER2- breast cancer from the TROPiCS-02 at ESMO. Oncology clinical development head Bill Grossman talked with Scrip about how it differs from rival Enhertu.
You may also be interested in...
Even with top-seller Biktarvy and its preventive therapy, Descovy, protected beyond this decade from generics, Gilead is investing aggressively in long-acting HIV candidates and its oncology pipeline.
The company has eight lung cancer trials running and plans for nine by the end of the year, including five with Trodelvy alone. Gilead is also looking ahead to an FDA verdict on lenacapavir.
With its HIV portfolio benefitting from a post-pandemic recovery, the drug maker said demand for Biktarvy drove higher US and Europe sales, while oncology products saw growth of 79% year-over-year.